Cognitive FunctionNCT07755475
A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Function and Energy Levels
A study testing Cellular Hydration Supplement in people with Cognitive Function and Fatigue, run by Artah Nutrition Limited at 1 site in United States.
Trial summary
This study evaluates the effects of Artah's Cellular Hydration electrolyte supplement on cognitive function and energy levels in healthy adults aged 25-60 who experience mild to moderate fatigue, brain fog, or related symptoms. Read more about this study
- Who is it for?
- Ages 25 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognitive Function, Fatigue, Energy Levels
- What is being tested?
- Cellular Hydration Supplement
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Jun 2025to 16 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Be male or female.
- Be aged 25-60.
- Anyone currently experiencing mild to moderate issues with at least three of the following: low energy or fatigue
- difficulty concentrating or low mental sharpness
- experiences of brain fog or lack of mental clarity
- feeling of low productivity
Show all 14Show fewer
- muscle weakness
- unwanted food cravings.
- Undertakes moderate to high-intensity exercise such as jogging/running and/or heavy resistance training at least three times per week.
- Willing to refrain from taking any products, medications, or supplements that target energy, cognition, or physical performance during the test period.
- Anyone with a BMI 18.5 to 30.
- Anyone who has access to a device (e.g., smartphone, laptop, computer) for reliable internet.
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
- Anyone willing to maintain a consistent diet and physical activity throughout study duration.
Who cannot join
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone suffering from gastrointestinal disorders including but not limited to small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), and celiac disease.
- Anyone suffering from hyperkalemia (high potassium), liver disease, or kidney disease.
- Anyone taking ACE inhibitors or potassium-sparing diuretics, examples include: Spironolactone (Aldactone), Eplerenone (Inspra), Amiloride (Midamor), Triamterene (Maxzide), Lisinopril (Zestril, Prinivil), Enalapril (Vasotec), Ramipril (Altace), Benazepril (Lotensin), Quinapril (Accupril), Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar), Irbesartan (Avapro), Lithium carbonate (Lithobid, Eskalith).
- Anyone taking antibiotics.
- Anyone with any allergies or sensitivities to any of the study product ingredients.
Show all 13Show fewer
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
- Anyone unwilling to follow the study protocol.
- Anyone with a history of substance abuse.
- Anyone who is a shift worker with an irregular sleep-wake cycle.
- Anyone who drinks heavily (8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
- Anyone who is currently a smoker or has been a smoker in the past 3 months.
- Currently partaking in another research study, or planning to at any point during this study's duration.
Trial locations and contacts
1 site in 1 country.
About this study
This study evaluates the effects of Artah's Cellular Hydration electrolyte supplement on cognitive function and energy levels in healthy adults aged 25-60 who experience mild to moderate fatigue, brain fog, or related symptoms. The trial is a single-arm, unblinded, virtual study in which all 50 participants will use the test product daily for 4 weeks.
Participants will complete self-reported questionnaires at Baseline, Week 1, Week 2, Week 3, and Week 4, and will undergo cognitive battery testing at Baseline and Week 4. The primary endpoint is change in cognitive performance scores as measured by a standardized cognitive battery. Secondary endpoints include participants' self-reported perceptions of mental clarity, alertness, mood, physical performance, overall energy levels, and frequency of food cravings.
- Conditions
- Cognitive Function, Fatigue, Energy Levels, Mental Clarity, Brain Fog, Food Cravings
- Being tested
- Cellular Hydration Supplement
- Medical subject headings
- Fatigue, Mental Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cellular Hydration SupplementDietary supplement
All 50 participants receive the Artah Cellular Hydration electrolyte supplement taken twice daily (once in the morning before the first meal and once in the afternoon after lunch or before evening exercise) as one teaspoon (approximately 7 g) stirred into 750 ml of water for 4 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Cellular Hydration Supplement | Active comparator | Not described Receives: Dietary Supplement: Cellular Hydration Supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Cognitive Battery Test Score (Polygons)
Change in processing speed and information sorting ability assessed via the Polygons timed cognitive battery subtest
Measured: Baseline and Week 4
Change in Cognitive Battery Test Score (Double Trouble)
Change in selective attention and processing speed assessed via the Double Trouble timed cognitive battery subtest (Stroop-based)
Measured: Baseline and Week 4
Change in Cognitive Battery Test Score (Feature Match)
Change in focus and processing speed assessed via the Feature Match timed cognitive battery subtest
Measured: Baseline and Week 4
Change in Cognitive Battery Test Score (Paired Associates)
Change in memory recall assessed via the Paired Associates performance-based cognitive battery subtest
Measured: Baseline and Week 4
Change in Cognitive Battery Test Score (Digit Span)
Change in short-term memory and cognitive flexibility assessed via the Digit Span performance-based cognitive battery subtest
Measured: Baseline and Week 4
Change in Cognitive Battery Test Score (Spatial Planning)
Change in executive function and logical decision-making assessed via the Spatial Planning timed cognitive battery subtest
Measured: Baseline and Week 4
Secondary outcomes (6)
Change in Self-Reported Mental Clarity and Focus
Assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Alertness
Assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Mood
Assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Physical Performance
Assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Overall Energy Levels
Assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Frequency of Food Cravings
Assessed via self-reported questionnaire
Measured: Baseline, Week 1, Week 2, Week 3, and Week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2026
- Study start13 Jun 2025
- Primary completion16 Aug 2025
- Study completion16 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognitive FunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Artah Nutrition Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07755475
- Sponsor's protocol ID
- 20772
- Other IDs
- legacy-20772
- Status last verified
- Aug 2026
- First submitted
- 5 Aug 2026
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Function and Energy Levels
- ClinicalTrials.gov ID
- NCT07755475
- Acronym / sponsor ID
- 20772
- Conditions
- Cognitive Function, Fatigue, Energy Levels, Mental Clarity, Brain Fog, Food Cravings
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Artah Nutrition LimitedIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 13 Jun 2025 (actual)
- Primary completion
- 16 Aug 2025 (actual)
- Study completion
- 16 Aug 2025 (actual)
- First posted
- 10 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effects of Artah's Cellular Hydration electrolyte supplement on cognitive function and energy levels in healthy adults aged 25-60 who experience mild to moderate fatigue, brain fog, or related symptoms. The trial is a single-arm, unblinded, virtual study in which all 50 participants will use the test product daily for 4 weeks.
Participants will complete self-reported questionnaires at Baseline, Week 1, Week 2, Week 3, and Week 4, and will undergo cognitive battery testing at Baseline and Week 4. The primary endpoint is change in cognitive performance scores as measured by a standardized cognitive battery. Secondary endpoints include participants' self-reported perceptions of mental clarity, alertness, mood, physical performance, overall energy levels, and frequency of food cravings.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cellular Hydration Supplement | Active comparator | Dietary Supplement: Cellular Hydration Supplement |
Who may qualify
- Ages
- 25 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (14 listed)
- Be male or female.
- Be aged 25-60.
- Anyone currently experiencing mild to moderate issues with at least three of the following: low energy or fatigue
- difficulty concentrating or low mental sharpness
- experiences of brain fog or lack of mental clarity
Key exclusion criteria (13 listed)
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone suffering from gastrointestinal disorders including but not limited to small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), and celiac disease.
- Anyone suffering from hyperkalemia (high potassium), liver disease, or kidney disease.
- Anyone taking ACE inhibitors or potassium-sparing diuretics, examples include: Spironolactone (Aldactone), Eplerenone (Inspra), Amiloride (Midamor), Triamterene (Maxzide), Lisinopril (Zestril, Prinivil), Enalapril (Vasotec), Ramipril (Altace), Benazepril (Lotensin), Quinapril (Accupril), Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar), Irbesartan (Avapro), Lithium carbonate (Lithobid, Eskalith).
- Anyone taking antibiotics.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cellular Hydration SupplementAll 50 participants receive the Artah Cellular Hydration electrolyte supplement taken twice daily (once in the morning before the first meal and once in the afternoon after lunch or before evening exercise) as one teaspoon (approximately 7 g) stirred into 750 ml of water for 4 weeks. | Dietary supplement | Cellular Hydration Supplement |
Primary outcome
Change in Cognitive Battery Test Score (Polygons)
Time frame: Baseline and Week 4
Change in processing speed and information sorting ability assessed via the Polygons timed cognitive battery subtest
Change in Cognitive Battery Test Score (Double Trouble)
Time frame: Baseline and Week 4
Change in selective attention and processing speed assessed via the Double Trouble timed cognitive battery subtest (Stroop-based)
Change in Cognitive Battery Test Score (Feature Match)
Time frame: Baseline and Week 4
Change in focus and processing speed assessed via the Feature Match timed cognitive battery subtest
Change in Cognitive Battery Test Score (Paired Associates)
Time frame: Baseline and Week 4
Change in memory recall assessed via the Paired Associates performance-based cognitive battery subtest
Change in Cognitive Battery Test Score (Digit Span)
Time frame: Baseline and Week 4
Change in short-term memory and cognitive flexibility assessed via the Digit Span performance-based cognitive battery subtest
Change in Cognitive Battery Test Score (Spatial Planning)
Time frame: Baseline and Week 4
Change in executive function and logical decision-making assessed via the Spatial Planning timed cognitive battery subtest
6 secondary outcomes
Change in Self-Reported Mental Clarity and Focus
Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Alertness
Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Mood
Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Physical Performance
Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Overall Energy Levels
Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Change in Self-Reported Frequency of Food Cravings
Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
Related trials for Cognitive Function
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cellular Hydration Supplement in people with Cognitive Function and Fatigue, run by Artah Nutrition Limited at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Cognitive Battery Test Score (Polygons) (time frame: Baseline and Week 4). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.